Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Impaired cognitive functioning in patients with tyrosinemia type i receiving nitisinone

Bendadi, Fatiha ; De Koning, Tom J. LU ; Visser, Gepke ; Prinsen, Hubertus C.M.T. ; De Sain, Monique G.M. ; Verhoeven-Duif, Nanda ; Sinnema, Gerben ; Van Spronsen, Francjan J. and Van Hasselt, Peter M. (2014) In Journal of Pediatrics 164(2). p.398-401
Abstract

Objective To examine cognitive functioning in patients with tyrosinemia type I treated with nitisinone and a protein-restricted diet. Study design We performed a cross-sectional study to establish cognitive functioning in children with tyrosinemia type I compared with their unaffected siblings. Intelligence was measured using age-appropriate Wechsler Scales. To assess cognitive development over time, we retrieved sequential IQ scores in a single-center subset of patients. We also evaluated whether plasma phenylalanine and tyrosine levels during treatment was correlated with cognitive development. Results Average total IQ score in 10 patients with tyrosinemia type I receiving nitisinone was significantly lower compared with their... (More)

Objective To examine cognitive functioning in patients with tyrosinemia type I treated with nitisinone and a protein-restricted diet. Study design We performed a cross-sectional study to establish cognitive functioning in children with tyrosinemia type I compared with their unaffected siblings. Intelligence was measured using age-appropriate Wechsler Scales. To assess cognitive development over time, we retrieved sequential IQ scores in a single-center subset of patients. We also evaluated whether plasma phenylalanine and tyrosine levels during treatment was correlated with cognitive development. Results Average total IQ score in 10 patients with tyrosinemia type I receiving nitisinone was significantly lower compared with their unaffected siblings (71 ± 13 vs 91 ± 13; P =.008). Both verbal and performance IQ subscores differed (77 ± 14 vs 95 ± 11; P <.05 and 70 ± 11 vs 87 ± 15; P <.05, respectively). Repeated IQ measurements in a single-center subset of 5 patients revealed a decline in average IQ score over time, from 96 ± 15 to 69 ± 11 (P <.001). No significant association was found between IQ score and either plasma tyrosine or phenylalanine concentration. Conclusion Patients with tyrosinemia type I treated with nitisinone are at risk for impaired cognitive function despite a protein-restricted diet.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
2-[2-nitro-4-trifluoromethylbenzoyl]-1, 3-cyclohexanedione, NTBC
in
Journal of Pediatrics
volume
164
issue
2
pages
4 pages
publisher
Academic Press
external identifiers
  • scopus:84892829474
  • pmid:24238861
ISSN
0022-3476
DOI
10.1016/j.jpeds.2013.10.001
language
English
LU publication?
no
id
bbe945fb-b3d1-47e6-9255-6759e5f637ad
date added to LUP
2020-02-26 10:09:41
date last changed
2024-08-07 15:49:04
@article{bbe945fb-b3d1-47e6-9255-6759e5f637ad,
  abstract     = {{<p>Objective To examine cognitive functioning in patients with tyrosinemia type I treated with nitisinone and a protein-restricted diet. Study design We performed a cross-sectional study to establish cognitive functioning in children with tyrosinemia type I compared with their unaffected siblings. Intelligence was measured using age-appropriate Wechsler Scales. To assess cognitive development over time, we retrieved sequential IQ scores in a single-center subset of patients. We also evaluated whether plasma phenylalanine and tyrosine levels during treatment was correlated with cognitive development. Results Average total IQ score in 10 patients with tyrosinemia type I receiving nitisinone was significantly lower compared with their unaffected siblings (71 ± 13 vs 91 ± 13; P =.008). Both verbal and performance IQ subscores differed (77 ± 14 vs 95 ± 11; P &lt;.05 and 70 ± 11 vs 87 ± 15; P &lt;.05, respectively). Repeated IQ measurements in a single-center subset of 5 patients revealed a decline in average IQ score over time, from 96 ± 15 to 69 ± 11 (P &lt;.001). No significant association was found between IQ score and either plasma tyrosine or phenylalanine concentration. Conclusion Patients with tyrosinemia type I treated with nitisinone are at risk for impaired cognitive function despite a protein-restricted diet.</p>}},
  author       = {{Bendadi, Fatiha and De Koning, Tom J. and Visser, Gepke and Prinsen, Hubertus C.M.T. and De Sain, Monique G.M. and Verhoeven-Duif, Nanda and Sinnema, Gerben and Van Spronsen, Francjan J. and Van Hasselt, Peter M.}},
  issn         = {{0022-3476}},
  keywords     = {{2-[2-nitro-4-trifluoromethylbenzoyl]-1, 3-cyclohexanedione; NTBC}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{2}},
  pages        = {{398--401}},
  publisher    = {{Academic Press}},
  series       = {{Journal of Pediatrics}},
  title        = {{Impaired cognitive functioning in patients with tyrosinemia type i receiving nitisinone}},
  url          = {{http://dx.doi.org/10.1016/j.jpeds.2013.10.001}},
  doi          = {{10.1016/j.jpeds.2013.10.001}},
  volume       = {{164}},
  year         = {{2014}},
}